找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi

[复制链接]
查看: 28867|回复: 53
发表于 2025-3-21 18:45:49 | 显示全部楼层 |阅读模式
书目名称Chemotherapy for Leukemia
副标题Novel Drugs and Trea
编辑Takanori Ueda
视频video
概述Elucidates the latest progress in chemotherapy for leukemia and related diseases.Presents prospective results of basic and preclinical studies for leukemia.Maximizes reader insight into modern treatme
图书封面Titlebook: Chemotherapy for Leukemia; Novel Drugs and Trea Takanori Ueda Book 2017 Springer Nature Singapore Pte Ltd. 2017 Acute promyelocytic leukemi
描述.This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells...This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also o
出版日期Book 2017
关键词Acute promyelocytic leukemia; Chronic myeloid leukemia; Molecular targeted agent; antimetabolite analog
版次1
doihttps://doi.org/10.1007/978-981-10-3332-2
isbn_softcover978-981-10-9844-4
isbn_ebook978-981-10-3332-2
copyrightSpringer Nature Singapore Pte Ltd. 2017
The information of publication is updating

书目名称Chemotherapy for Leukemia影响因子(影响力)




书目名称Chemotherapy for Leukemia影响因子(影响力)学科排名




书目名称Chemotherapy for Leukemia网络公开度




书目名称Chemotherapy for Leukemia网络公开度学科排名




书目名称Chemotherapy for Leukemia被引频次




书目名称Chemotherapy for Leukemia被引频次学科排名




书目名称Chemotherapy for Leukemia年度引用




书目名称Chemotherapy for Leukemia年度引用学科排名




书目名称Chemotherapy for Leukemia读者反馈




书目名称Chemotherapy for Leukemia读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

1票 100.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:25:20 | 显示全部楼层
发表于 2025-3-22 01:20:32 | 显示全部楼层
Imatinib: Clinical Pharmacology and Therapeutic Resultsd with improved prognosis in several studies. Furthermore, approximately 40% of patients who exhibited sustained deep molecular response could maintain treatment-free remission after discontinuation of imatinib. Treatment-free remission is now considered to be a new goal of tyrosine kinase inhibitor
发表于 2025-3-22 06:41:10 | 显示全部楼层
Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Basic Results and Pharmacokineticsimab resistance in the treatment of chronic lymphocytic leukemia (CLL). The characteristic toxicities of rituximab are infusion reactions, late-onset neutropenia, hepatitis B virus reactivation, and opportunistic infections..Alemtuzumab is a humanized anti-CD52 mAb and the first mAb to be approved f
发表于 2025-3-22 12:35:13 | 显示全部楼层
发表于 2025-3-22 16:33:36 | 显示全部楼层
发表于 2025-3-22 18:08:25 | 显示全部楼层
发表于 2025-3-23 01:10:09 | 显示全部楼层
Retinoic Acid, All-, Retinoic Acid (ATRA), and Tamibaroteney in both untreated APL patients and relapsed patients who have been treated with ATRA and chemotherapy. Retinoids are a model of the development of new molecular-targeted agents for other malignant tumors.
发表于 2025-3-23 04:05:25 | 显示全部楼层
Nelarabinetravenous (IV) infusion given over 2 h on days 1, 3, and 5 and repeated every 21 days. In pediatric patients, the recommended dose is 650 mg/m. IV given over 1 h for five consecutive days and repeated every 21 days. In a large phase II study conducted by the German Multicenter Study Group for Adult
发表于 2025-3-23 08:13:27 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-5 18:51
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表